Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
FDA-2026-N-4162-0001Notice
Comments
4
Awaiting comments
Deadline
Closed on Jun 18, 2026
Closed Jun 18, 2026
Net supportiSupport minus oppose · campaigns included
+100%
+100% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
- Posted
- May 22, 2026
- Comment period
- May 22, 2026 – Jun 18, 2026
- FR Doc
- 2026-10321
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+100%
Net support
Support4
Aggregates include form-letter campaigns. Excluding them, net support is +100% across organic comments.
Who commented
Breakdown by commenter type.
Individual
3
Advocacy
1
Comments over time
Weekly arrivals, stacked by stance.
Posted May 22, 2026Deadline Jun 18, 2026
May 18May 25
Support4Oppose0Other0
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
100%
0%
0%
Advocacy
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Vaccine updates and accessibility |
|---|
1 organization-typed comment could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.